Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
Sign Up to like & getrecommendations! Published in 2020 at "Archives of pharmacal research"
DOI: 10.1007/s12272-020-01245-y
Abstract: Factor VIII (FVIII) is a blood coagulation protein that circulates as a complex with von Willebrand factor (vWF) in the plasma. In the survey of inhibitors in plasma product exposed toddlers (SIPPET) study, plasma-derived FVIII… read more here.
Keywords: purification; fviii; von willebrand; factor ... See more keywords
Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2021.12.038
Abstract: BACKGROUND&AIMS It has been suggested that the ratio of procoagulant factor VIII to anticoagulant protein C (FVIII/PC) reflects the haemostatic equilibrium. Moreover, FVIII/PC predicted decompensation/death in a small study not accounting for portal hypertension severity.… read more here.
Keywords: hypercoagulable state; liver disease; fviii; factor viii ... See more keywords
The lesson learned from the new c.2547-1G>T mutation combined with p.R854Q:when a type 2N mutation reveals a quantitative von Willebrand factor defect.
Sign Up to like & getrecommendations! Published in 2022 at "Thrombosis and haemostasis"
DOI: 10.1055/a-1777-6881
Abstract: Type 2N is a rare von Willebrand disease (VWD) variant involving an impairment in the FVIII carrier function of von Willebrand factor (VWF). It has a phenotype that mimics hemophilia A, and FVIII binding to… read more here.
Keywords: fviii; vwf; von willebrand; vwf fviiib ... See more keywords
Sensitive measurement of clinically relevant factor VIII levels in thrombin generation assays requires presence of factor XIa.
Sign Up to like & getrecommendations! Published in 2023 at "Thrombosis and haemostasis"
DOI: 10.1055/a-2101-7961
Abstract: BACKGROUND Hemophilia A (HA) is characterized by decreased or absent FVIII. Current FVIII assays are based on clotting time and only provide information about the initiation of coagulation. In contrast, thrombin generation assays (TGA) can… read more here.
Keywords: thrombin generation; fviii; generation; generation assays ... See more keywords
Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sign Up to like & getrecommendations! Published in 2017 at "Human gene therapy"
DOI: 10.1089/hum.2017.016
Abstract: While therapeutic expression of coagulation factors from adeno-associated virus (AAV) vectors has been successfully achieved in patients with hemophilia, neutralizing antibodies to the vector and inhibitory antibodies to the transgene severely limit efficacy. Indeed, approximately… read more here.
Keywords: fviii; associated virus; neutralizing antibodies; adeno associated ... See more keywords
Characterisation and application of recombinant FVIII‐neutralising antibodies from haemophilia A inhibitor patients
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17227
Abstract: The development of anti‐drug antibodies (ADAs) is a serious outcome of treatment strategies involving biological medicines. Coagulation factor VIII (FVIII) is used to treat haemophilia A patients, but its immunogenicity precludes a third of severe… read more here.
Keywords: application recombinant; fviii; characterisation application; fviii neutralising ... See more keywords
FVIII p.Arg1800His mutation is associated with mild/moderate hemophilia A in Chinese population
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Laboratory Hematology"
DOI: 10.1111/ijlh.12851
Abstract: Sir, Hemophilia A (HA) is the most common Xlinked bleeding disorder caused by absent, reduced, or dysfunction of factor FVIII coagulant activity (FVIII:C) due to mutations in the F8 gene. In mild/ moderate hemophilia A… read more here.
Keywords: mild moderate; fviii arg1800his; arg1800his mutation; fviii ... See more keywords
Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Laboratory Hematology"
DOI: 10.1111/ijlh.13384
Abstract: Dear Editors: Development of antibodies interfering with the function of factor VIII (FVIII) replacement products is one of the most significant complications in the treatment of hemophilia A (HA). Laboratory testing for such antibodies, called… read more here.
Keywords: plasma; bethesda assay; treatment; fviii ... See more keywords
New treatment paradigm for hemophilia poses challenges for legacy bioassays
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.14550
Abstract: The one‐stage factor VIII (FVIII) clotting assay measures the extent by which a plasma sample corrects the coagulation time of FVIII‐ deficient plasma in an activated partial thromboplastin time (aPTT)‐ based assay.1 The availability of… read more here.
Keywords: treatment; one stage; fviii; fviii assays ... See more keywords
Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.15665
Abstract: Acquired hemophilia A (AHA) is a rare bleeding disorder caused by functional insufficiency of coagulation factor VIII (FVIII). Autoantibodies targeting FVIII may neutralize its procoagulant effect, thereby causing severe bleeding. Such inhibitory autoantibodies have been… read more here.
Keywords: antisigg; spike protein; sequence; covid ... See more keywords
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Sign Up to like & getrecommendations! Published in 2017 at "Thrombosis and haemostasis"
DOI: 10.1160/th16-06-0444
Abstract: Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent… read more here.
Keywords: treatment; safety; fviii; efficacy ... See more keywords